Jefferies Group reaffirmed their hold rating on shares of Analogic (NASDAQ:ALOG) in a report published on Friday. The firm currently has a $80.00 price target on the medical research company’s stock. Jefferies Group also issued estimates for Analogic’s Q2 2018 earnings at $0.68 EPS, Q3 2018 earnings at $0.76 EPS, Q4 2018 earnings at $0.66 EPS, FY2018 earnings at $2.86 EPS, FY2019 earnings at $3.00 EPS, FY2020 earnings at $3.25 EPS, FY2021 earnings at $3.40 EPS and FY2022 earnings at $3.57 EPS.
Several other research firms also recently weighed in on ALOG. Zacks Investment Research upgraded Analogic from a hold rating to a buy rating and set a $97.00 price target on the stock in a research note on Friday. BidaskClub downgraded Analogic from a hold rating to a sell rating in a research note on Thursday, December 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $88.33.
Shares of Analogic (NASDAQ ALOG) opened at $84.80 on Friday. The firm has a market capitalization of $1,073.69, a P/E ratio of 44.10, a P/E/G ratio of 4.30 and a beta of 0.86. Analogic has a 52 week low of $66.00 and a 52 week high of $88.45.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.10 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.40 annualized dividend and a yield of 0.47%. Analogic’s dividend payout ratio is -6.99%.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Citadel Advisors LLC lifted its holdings in shares of Analogic by 88.8% during the 2nd quarter. Citadel Advisors LLC now owns 128,879 shares of the medical research company’s stock valued at $9,363,000 after buying an additional 60,614 shares during the period. Renaissance Technologies LLC bought a new position in shares of Analogic during the 1st quarter valued at $1,252,000. Vanguard Group Inc. lifted its holdings in shares of Analogic by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,147,408 shares of the medical research company’s stock valued at $83,359,000 after buying an additional 34,765 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Analogic by 470.7% during the 2nd quarter. SG Americas Securities LLC now owns 7,619 shares of the medical research company’s stock valued at $554,000 after buying an additional 6,284 shares during the period. Finally, TIAA CREF Investment Management LLC lifted its holdings in shares of Analogic by 33.1% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 56,358 shares of the medical research company’s stock valued at $4,094,000 after buying an additional 14,022 shares during the period. Institutional investors and hedge funds own 97.82% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://stocknewstimes.com/2017/12/12/analogic-alog-stock-rating-reaffirmed-by-jefferies-group.html.
Analogic Corporation designs, manufactures and commercializes guidance, diagnostic imaging and threat detection technologies. The Company operates through three segments: Medical Imaging, Ultrasound, and Security and Detection. The Company’s Medical Imaging segment provides medical imaging systems and subsystems for computed tomography (CT), magnetic resonance imaging (MRI) and high-resolution digital mammography.
Receive News & Ratings for Analogic Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Analogic Co. and related companies with MarketBeat.com's FREE daily email newsletter.